Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 1;11:1197484. doi: 10.3389/fbioe.2023.1197484

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Gan, Ji, Zhang, Chen, Yao and Ren.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Lar@Fe-MOF exhibited the strongest in vivo antitumor efficacy. (A) Treatment scheme of saline, Lar, and Lar@Fe-MOF. (B) Tumor growth curve with different treatments (n = 5). (C) Tumor weights 7 days after the end of treatment (n = 5). (D) HE staining of tumors collected 7 days after the end of treatment. (E) TUNEL staining of tumors collected 7 days after the end of treatment. Lar@Fe-MOF treatment resulted in the highest apoptotic ratio.